Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Abstract: A method includes decoding, by at least one hardware processor, a notification of a changed database code of a database. A query is executed responsive to the notification. The query indicates a data processing command and a data object in the database. A regression in the changed database code is detected based on multiple regression testing operations applied to the data processing command and the data object. Analysis of the regression is performed to detect a rollout parameter of a plurality of rollout parameters as a root cause of the regression. The plurality of rollout parameters are associated with the changed database code. A determination is made on whether to perform a mitigation action for the regression based on the rollout parameter.

Abstract: A container kernel upgrade based on a programmable container kernel, includes, in response to receiving a container kernel upgrade request, freezing an application container in which a to-be-upgraded first container kernel is located. Current container status data of an application container including first container kernel status data and application status data is stored. The application container is restarted by using a second container kernel used for upgrading a container kernel, where restarted container status data of the restarted application container includes second container kernel status data corresponding to the second container kernel when the application container is restarted. Using the stored current container status data, a corresponding data field is updated in a data structure of the restarted container status data.

Abstract: Chimeric antigen receptors targeting CD20 and preparation methods thereof are provided. The antigen binding region of the chimeric antigen receptor may include a heavy chain variable region shown in SEQ ID NOs: 7, 9 or 33 and a light chain variable region shown in SEQ ID NOs: 11, 13 or 35.

Abstract: A bifunctional catalyst and a preparation method therefor are provided. The bifunctional catalyst is prepared by providing carbon matrix, adding 0.01-10 mol/L platinum containing solution, 0.01-10 mol/L palladium containing solution, 0.01-10 mol/L silver containing solution, and 0.01-15 mol/L sodium citrate trihydrate solution to the carbon matrix for reacting at 20° C. to 80° C. for 0.5 h to 24 h to obtain a mixed solution, and adding reducing agent to the mixed solution for reacting for 0.5 h to 30 h, and centrifuging and drying so as to obtain the bifunctional catalyst.

Abstract: The present disclosure provides BCMA-targeted chimeric antigen receptors (CARs) as well as preparation methods and applications thereof. The CARs of the present disclosure targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and a scFv targeting CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Abstract: The present disclosure provides systems, kits and methods for determining the copy number of a mouse TCR transgene. The primers are specific to the conserved regions of the mouse TCR gene. The primers/probes provide good amplification efficiency and can quickly and accurately determine the copy number of a mouse TCR transgene.

Abstract: Anti-BCMA antibodies and chimeric antigen receptors (CARs) are provided. Immune cells expressing the anti-BCMA CAR can be used to treat cancer. The anti-BCMA antibodies and CARs can recognize the extracellular domains of human BCMA. The anti-BCMA CAR T cells show specific cytotoxicity towards BCMA-positive target cells.

Abstract: Provided are a CD22-targeted chimeric antigen receptor, a preparation method therefor and an application thereof. The chimeric antigen receptor comprises a leader sequence, a CD22-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal domain. Provided are a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and an application thereof. The chimeric antigen receptor targets CD22 positive cells and can be used for treating CD22-positive B-cell leukemia, and some CD19-negative and CD22-positive patients in which acute B-cell leukemia has recurred after anti-CD19 CAR-T treatment.

Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Abstract: Provided is a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, provided is a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. Provided is a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor shows extremely high killing ability against tumor cells. The chimeric antigen receptor targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

Abstract: The present disclosure relates to an anti-counterfeiting image code embedded in a decorative pattern of a ceramic tile and an anti-counterfeiting method thereof, the anti-counterfeiting image code is input into a terminal recognition software application. The anti-counterfeiting method includes steps of: (1) embedding an image code into the decorative pattern of the ceramic tile; (2) inputting the decorative pattern on a surface of the ceramic tile into an image code generating software to generate the image code that can be decoded, editing a ceramic tile parameter and ceramic tile information in the image code generating software; (3) packing the image code and inputting it into a terminal recognition software application; (4) downloading the terminal recognition software application at a mobile terminal; and (5) opening an application to initiate a code scanner and capturing a image or a pre-taught partial feature image.